Here, we administered R-EPOCH as a first-line regimen in DLBCL patients with high Ki-67 expression and compared the treatment efficacy of R-EPOCH and R-CHOP therapy in this subgroup using matched-pair controls. This evidence concerns the gene MKI67 and diffuse large B-cell lymphoma.